Evidence map›Paper›PMID 30030127›Full record

ArticlePharmacology, biochemistry, and behavior2018

Recovery from behavior and developmental effects of chronic oral methylphenidate following an abstinence period.

Connor Martin, Dennis Fricke, Abisha Vijayashanthar, Courtney Lowinger, Dimitris Koutsomitis, Daniel Popoola, Michael Hadjiargyrou, David E Komatsu, Panayotis K Thanos

Abstract read
In one paragraph

Article in Pharmacology, biochemistry, and behavior, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Connor MartinBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA.
Dennis FrickeBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA.
Abisha VijayashantharBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA.
Courtney LowingerBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA.
Dimitris KoutsomitisBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA.
Daniel PopoolaBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA.
Michael HadjiargyrouNew York Institute of Technology, Department of Life Sciences, Old Westbury, NY, USA.
David E KomatsuStony Brook University, Department of Orthopedics, Stony Brook, NY, USA.
Panayotis K ThanosBehavioral Neuropharmacology and Neuroimaging Laboratory on Addictions, Research Institute on Addictions, Department of Pharmacology & Toxicology, Jacobs School of Medicine and Biosciences, University at Buffalo, Buffalo, NY, USA. Electronic address: pthanos@ria.buffalo.edu.

Funding

RESEARCH TRAINING ON ALCOHOL ETIOLOGY AND TREATMENTT32AA007583 · NIAAA · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Gregory G Homish, KENNETH E LEONARD · 2000 to 2026
$8.5M
Skeletal Effects of MethylphenidateR01HD070888 · NICHD · STATE UNIVERSITY NEW YORK STONY BROOK · PI KOMATSU, DAVID E · 2013 to 2017
$1.6M
NIAAA NIH HHS T32 AA007583NICHD NIH HHS R01 HD070888
6 · The paper itself

Abstract

Chronic oral methylphenidate (MP) exposure in rats is associated with numerous developmental and behavioral consequences. The present study investigated the persistence of the effects of chronic oral MP exposure after abstinence from MP use. Male and female rats were exposed to daily orally self-administered water, low dose MP (LD), or high dose (HD) MP for 13 weeks, followed by a 4-week abstinence period. Fluid, food consumption and bodyweights were monitored and animals were tested for locomotor activity, anxiety- and depressive-like symptoms, learning and memory, and social behavior during both the treatment and abstinence phases of the experiment. During treatment, MP attenuated bodyweight regardless of sex, but increased food and fluid consumption in females and males by 20.7% and 30.1%, respectively. MP also increased locomotor activity in both males and females observed as increased distance travelled in an open field. (59.1% and 95.9%, respectively) and increased locomotor activity in the home cage over a 24-hour circadian cycle (45.5% and 63.0%). Additionally, MP exerted an anxiolytic effect observed as increased time spent in the open arms of an elevated plus maze (31.1% in HD males, 59.2% in HD females), and an increased latency to immobility in a forced swim test (330% in HD males, 418% in HD females). The effects of MP (bodyweight, consumption, locomotion, anxiolytic, and anti-depressive) were, almost without exception, eliminated during the abstinence period. MP had no impact on learning and memory performance as measured by a T-maze, or social behavior during treatment. These findings suggest that the behavioral consequences of chronic oral MP treatment in our preclinical model are reversible in rats following an abstinence period from use of the drug.

Indexed as

Substance Withdrawal SyndromeAdministration, OralAnimalsCentral Nervous System StimulantsFemaleMaleMethylphenidateRatsRats, Sprague-DawleyCentral Nervous System StimulantsMethylphenidateAnxietyAttention Deficit Hyperactivity DisorderMethylphenidatePsychostimulantRitalinSensitization

Identifiers

PMID30030127
PMCPMC6319957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.